350 Fifth Avenue
72nd Floor Suite 7240
New York, NY 10118
Full Time Employees: 56
|Mr. Joern Aldag||Chief Exec. Officer||574.31k||N/A||1959|
|Dr. Reinhard Kandera||Chief Financial Officer||407.36k||N/A||1969|
|Dr. Igor Matushansky M.D., Ph.D.||Chief Medical Officer and Global Head of R&D||526.72k||N/A||1973|
|Mr. Daniel Pinschewer||Co-Founder & Chief Scientific Officer||N/A||N/A||1975|
|Prof. Rolf M. Zinkernagel Ph.D., M.D.||Co-Founder||N/A||N/A||1944|
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
HOOKIPA Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.